tiprankstipranks
Advertisement
Advertisement

ZNTL Stock Latest News

Zentalis Pharmaceuticals Expands Board, Appoints New Director
Company AnnouncementsZentalis Pharmaceuticals Expands Board, Appoints New Director
16d ago
8K
ZNTL
Analyst Reiterates Buy on Zentalis as New MUIR Data Bolster Azenosertib Outlook; $10 Price Target Unchanged
PremiumRatings
Analyst Reiterates Buy on Zentalis as New MUIR Data Bolster Azenosertib Outlook; $10 Price Target Unchanged
21d ago
ZNTL
Zentalis Highlights Promising Azenosertib Data in Ovarian Cancer
PremiumCompany Announcements
Zentalis Highlights Promising Azenosertib Data in Ovarian Cancer
21d ago
8K
ZNTL
Zentalis: Buy Rating Reiterated as Azenosertib Strategy Advances; $10 Price Target Maintained on De-Risked Dosing and Late-Stage Catalysts
PremiumRatings
Zentalis: Buy Rating Reiterated as Azenosertib Strategy Advances; $10 Price Target Maintained on De-Risked Dosing and Late-Stage Catalysts
30d ago
ZNTL
Zentalis reports Q1 EPS (50c), consensus (52c)
PremiumThe Fly
Zentalis reports Q1 EPS (50c), consensus (52c)
1M ago
ZNTL
Zentalis Advances Azenosertib with New Trial Updates
PremiumCompany AnnouncementsZentalis Advances Azenosertib with New Trial Updates
1M ago
8K
ZNTL
ZNTL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
ZNTL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
1M ago
ZNTL
Zentalis Starts Pivotal Phase 3 ASPENOVA Ovarian Cancer Trial
Premium
Company Announcements
Zentalis Starts Pivotal Phase 3 ASPENOVA Ovarian Cancer Trial
1M ago
8K
ZNTL
Zentalis Highlights New Azenosertib Data in Breast Cancer
PremiumCompany Announcements
Zentalis Highlights New Azenosertib Data in Breast Cancer
2M ago
8K
ZNTL
Zentalis to present azenosertib preclinical data in TNBC at AACR meeting
PremiumThe Fly
Zentalis to present azenosertib preclinical data in TNBC at AACR meeting
2M ago
ZNTL
Midday Fly By: CoreWeave inks Anthropic, TSMC reports March sales bump
PremiumThe Fly
Midday Fly By: CoreWeave inks Anthropic, TSMC reports March sales bump
2M ago
E
MU
Zentalis price target raised to $10 from $6 at Guggenheim
PremiumThe Fly
Zentalis price target raised to $10 from $6 at Guggenheim
2M ago
ZNTL
Zentalis Advances Azenosertib Dose in DENALI Phase 2
PremiumCompany AnnouncementsZentalis Advances Azenosertib Dose in DENALI Phase 2
2M ago
8K
ZNTL
Advancing Azenosertib Pipeline and DENALI Readouts Underpin Buy Rating on Zentalis Pharmaceuticals
Premium
Ratings
Advancing Azenosertib Pipeline and DENALI Readouts Underpin Buy Rating on Zentalis Pharmaceuticals
3M ago
ZNTL
ZNTL Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
ZNTL Earnings this Week: How Will it Perform?
3M ago
ZNTL
Zentalis outlines 2026 milestones for azenosertib program
PremiumCompany Announcements
Zentalis outlines 2026 milestones for azenosertib program
5M ago
8K
ZNTL
Zentalis Pharmaceuticals: Balancing DENALI Momentum and ASPENOVA Visibility Against Pivotal Data and Execution Risk (Hold Rating Maintained)
PremiumRatings
Zentalis Pharmaceuticals: Balancing DENALI Momentum and ASPENOVA Visibility Against Pivotal Data and Execution Risk (Hold Rating Maintained)
5M ago
ZNTL
Zentalis provides update, key milestones in 2025, expectations for 2026
PremiumThe Fly
Zentalis provides update, key milestones in 2025, expectations for 2026
5M ago
ZNTL
Zentalis Pharmaceuticals Announces Stock Repurchase Agreement
PremiumCompany Announcements
Zentalis Pharmaceuticals Announces Stock Repurchase Agreement
6M ago
8K
ZNTL
Zentalis Pharmaceuticals Reports Q3 2025 Financial Results
PremiumCompany AnnouncementsZentalis Pharmaceuticals Reports Q3 2025 Financial Results
7M ago
ZNTL
Zentalis price target lowered to $4 from $8 at Morgan Stanley
Premium
The Fly
Zentalis price target lowered to $4 from $8 at Morgan Stanley
7M ago
ZNTL
Buy Rating for Zentalis Pharmaceuticals Driven by Promising Clinical Progress and Strategic Focus on PROC
Premium
Ratings
Buy Rating for Zentalis Pharmaceuticals Driven by Promising Clinical Progress and Strategic Focus on PROC
7M ago
ZNTL

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >